CRA consultants supported a pharmaceutical company in its successful challenge of an ANDA filed by a generic manufacturer. The generic company sought to manufacture and sell generic versions of two related diabetes treatments. CRA provided a report analyzing evidence of commercial success for the branded pharmaceutical products as well as deposition and trial testimony.
Trade Secret Litigation Watch: February 2026
In this second installment of the Trade Secret Litigation Watch, CRA’s Intellectual Property team examines emerging trends and case outcomes with an emphasis...